Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Fisher & Paykel HealthcareASX:FPH +0.41%91 Days Sales Outstanding is 47.06 as of Mar. 2026, which is 5% above its 10-year median of 44.62. GuruFocus rates ASX:FPH with a GF Score™ of 91/100 and a GF Value™ of A$36.82 (Fairly Valued). The stock has 3 warning signs investors should review. Among 810 Medical Devices & Instruments companies, Fisher & Paykel Healthcare ranks better than 76.79% on this metric.
The historical rank and industry rank for Fisher & Paykel Healthcare's Days Sales Outstanding or its related term are showing as below:
ASX:FPH'
s Days Sales Outstanding Range Over the Past 10 Years
Min: 36.81 Med: 44.62 Max: 69.89
Current: 45.78
During the past 13 years, Fisher & Paykel Healthcare's highest Days Sales Outstanding was 69.89. The lowest was 36.81. And the median was 44.62.
ASX:FPH's Days Sales Outstanding is ranked better than 76.79% of 810
companies
in the Medical Devices & Instruments industry
Industry Median: 65.25
vs ASX:FPH: 45.78
Fisher & Paykel Healthcare's Days Sales Outstanding
declined
from Mar. 2025 (142.19) to Mar. 2026 (47.06).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Fisher & Paykel Healthcare Days Sales Outstanding Chart
ASX:FPH vs ISRG, BDX, RMD: Days Sales Outstanding Comparison
For the Medical Instruments & Supplies subindustry, Fisher & Paykel Healthcare's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Fisher & Paykel Healthcare Days Sales Outstanding vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Fisher & Paykel Healthcare's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where Fisher & Paykel Healthcare's Days Sales Outstanding falls into.
Fisher & Paykel Healthcare Days Sales Outstanding Calculation
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Fisher & Paykel Healthcare (ASX:FPH) has a Days Sales Outstanding of 47.06 as of Mar. 2026. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Fisher & Paykel Healthcare and its competitors. This is near median its historical median of 44.62. Over the past decade, Fisher & Paykel Healthcare's Days Sales Outstanding has ranged from 36.81 to 69.89. According to the industry distribution chart, Fisher & Paykel Healthcare ranks #188 out of 810 companies in the Medical Devices & Instruments industry, placing it in the top 23.2%.
Is Fisher & Paykel Healthcare's Days Sales Outstanding too high?
Fisher & Paykel Healthcare's current Days Sales Outstanding of 47.06 is near median its 10-year median of 44.62. Over the past 10 years, this metric has ranged from a low of 36.81 to a high of 69.89. The Medical Devices & Instruments industry median Days Sales Outstanding is 65.25. Fisher & Paykel Healthcare's value of 47.06 is 27.9% below this industry median. Based on the distribution chart, Fisher & Paykel Healthcare ranks #188 out of 810 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Fisher & Paykel Healthcare has a GF Score™ of 91/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Fisher & Paykel Healthcare's Days Sales Outstanding compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Fisher & Paykel Healthcare ranks #188 out of 810 companies for Days Sales Outstanding. This places Fisher & Paykel Healthcare in the top 23% of its industry — outperforming the majority of peers. The industry median Days Sales Outstanding is 65.25. Fisher & Paykel Healthcare's value of 47.06 is 27.9% below this benchmark. Historically, Fisher & Paykel Healthcare's own Days Sales Outstanding has ranged from 36.81 to 69.89 over the past decade. While the company's 10-year median is 44.62 vs. the industry median of 65.25, Fisher & Paykel Healthcare has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Sales Outstanding for a Medical Devices & Instruments company?
The median Days Sales Outstanding among Medical Devices & Instruments companies is 65.25, based on 810 companies in the industry. Companies in the top quartile (top 25%) have a Days Sales Outstanding significantly above this median, while those in the bottom quartile fall well below. However, Days Sales Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Fisher & Paykel Healthcare's current Days Sales Outstanding of 47.06 is 27.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Sales Outstanding mean?
A high Days Sales Outstanding can signal that a stock is expensive relative to its fundamentals. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Fisher & Paykel Healthcare and its competitors. For the Medical Devices & Instruments industry, the median Days Sales Outstanding is 65.25 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Fisher & Paykel Healthcare's current Days Sales Outstanding is 47.06, which is near median its own 10-year median of 44.62. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fisher & Paykel Healthcare stock overvalued right now?
Based on GuruFocus' analysis, Fisher & Paykel Healthcare (ASX:FPH) is currently considered Fairly Valued. The stock's GF Value™ is A$36.82, compared to a current price of A$36.38 — trading 1.2% below its estimated fair value. The current Days Sales Outstanding is 47.06, which is near median its 10-year median of 44.62 and 27.9% below the Medical Devices & Instruments industry median of 65.25. Fisher & Paykel Healthcare's overall GF Score™ is 91/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Sales Outstanding calculated?
Days Sales Outstanding is calculated from a company's financial statements. For Fisher & Paykel Healthcare (ASX:FPH), the current Days Sales Outstanding is 47.06 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Fisher & Paykel Healthcare (ASX:FPH) Overvalued in 2026?
Based on GuruFocus' analysis, Fisher & Paykel Healthcare stock appears to be undervalued.
The current stock price of A$36.38 is trading 1.2% below its estimated GF Value™ of A$36.82.
GuruFocus considers Fisher & Paykel Healthcare to be Fairly Valued.
Key valuation signals for ASX:FPH:
Days Sales Outstanding: 47.06 (near median its 10-year median of 44.62)
GF Value™: A$36.82 vs. price of A$36.38 (1.2% below fair value)
Industry Position: 27.9% below the Medical Devices & Instruments median (#188 of 810)
No single metric tells the full story. See the ASX:FPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Fisher & Paykel Healthcare is one of the three largest respiratory care device companies globally. It is the market leader in hospital use of humidifiers, masks, and related consumables, and the number three player in the at-home treatment of sleep apnea using respiratory devices. Both the hospital and homecare markets for respiratory devices are growing strongly in the developed markets in which Fisher & Paykel has a presence. The company earns roughly half of its revenue in North America, around a quarter in Europe, and approximately a fifth in Asia-Pacific. Fisher conducts its own R&D and has thousands of patents and pending applications. It manufactures in New Zealand, Mexico, and China, and has a multichannel distribution model.
91GF Score
Get the complete analysis for ASX:FPH
Days Sales Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:FPH has been successfully added to your 
